1. Home
  2. MFIC vs PHAT Comparison

MFIC vs PHAT Comparison

Compare MFIC & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MidCap Financial Investment Corporation

MFIC

MidCap Financial Investment Corporation

HOLD

Current Price

$10.90

Market Cap

1.1B

Sector

Finance

ML Signal

HOLD

Logo Phathom Pharmaceuticals Inc.

PHAT

Phathom Pharmaceuticals Inc.

HOLD

Current Price

$13.79

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MFIC
PHAT
Founded
2004
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.1B
IPO Year
2004
2019

Fundamental Metrics

Financial Performance
Metric
MFIC
PHAT
Price
$10.90
$13.79
Analyst Decision
Hold
Strong Buy
Analyst Count
6
6
Target Price
$12.63
$17.33
AVG Volume (30 Days)
604.7K
1.3M
Earning Date
02-26-2026
03-05-2026
Dividend Yield
13.72%
N/A
EPS Growth
N/A
N/A
EPS
1.07
N/A
Revenue
$324,678,000.00
$147,190,000.00
Revenue This Year
$9.08
$221.76
Revenue Next Year
N/A
$81.67
P/E Ratio
$10.37
N/A
Revenue Growth
11.35
460.30
52 Week Low
$10.18
$2.21
52 Week High
$14.74
$18.31

Technical Indicators

Market Signals
Indicator
MFIC
PHAT
Relative Strength Index (RSI) 35.30 43.26
Support Level $11.10 $13.14
Resistance Level $11.25 $14.31
Average True Range (ATR) 0.23 0.82
MACD -0.04 -0.07
Stochastic Oscillator 8.96 23.53

Price Performance

Historical Comparison
MFIC
PHAT

About MFIC MidCap Financial Investment Corporation

MidCap Financial Investment Corp is an externally managed, publicly traded, closed-end, diversified management investment company. Its investment objective is to generate current income and, to a lesser extent, long-term capital appreciation. It predominantly invests in directly originated and privately negotiated first lien senior secured loans to privately held U.S. middle-market companies, and in other types of securities including, first lien unitranche, second lien senior secured, unsecured, subordinated, and mezzanine loans, and equities in both private and public middle market companies.

About PHAT Phathom Pharmaceuticals Inc.

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Share on Social Networks: